Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
| Revenue (TTM) | $25.27B |
| Gross Profit (TTM) | $16.35B |
| EBITDA | $6.92B |
| Operating Margin | 17.80% |
| Return on Equity | 15.20% |
| Return on Assets | 7.72% |
| Revenue/Share (TTM) | $66.06 |
| Book Value | $59.94 |
| Price-to-Book | 5.62 |
| Price-to-Sales (TTM) | 5.26 |
| EV/Revenue | 5.57 |
| EV/EBITDA | 21.87 |
| Quarterly Earnings Growth (YoY) | 14.20% |
| Quarterly Revenue Growth (YoY) | 2.60% |
| Shares Outstanding | $383.36M |
| Float | $347.57M |
| % Insiders | 5.37% |
| % Institutions | 82.11% |
Volatility is currently contracting
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.
SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.
New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery.
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SYK and any ticker you trade — then tracks every position and per-strategy win rate.
